SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

BRIEF-AbbVie Announces Late-Breaking Results From Phase 2 Trial Of Investigational Epcoritamab In Relapsed/Refractory Large B-Cell Lymphoma Patients

reuters.com · 06/11/2022 10:10
BRIEF-AbbVie Announces Late-Breaking Results From Phase 2 Trial Of Investigational Epcoritamab In Relapsed/Refractory Large B-Cell Lymphoma Patients

- Abbvie Inc ABBV:

  • ANNOUNCES LATE-BREAKING RESULTS FROM PHASE 2 TRIAL OF INVESTIGATIONAL EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

  • EPCORITAMAB SHOWS CLINICALLY MEANINGFUL EFFICACY IN CHALLENGING-TO-TREAT, HIGHLY REFRACTORY LBCL PATIENTS

Source text for Eikon: ID:nPn3SJpfCa

Further company coverage: ABBV


((reuters.briefs@thomsonreuters.com;))